NHSBSA - Freedom of Information

You are at: NHSBSA Home Page | Freedom of Information

Previous Request List - Detail

Request Reference: 7362 Request Date: 03 Jan 2018
Request: Dear Sirs, We are writing to make a request for information pursuant to the Freedom of Information Act 2000 (“FOIA”). This request is made by Morgan, Lewis & Bockius UK LLP on behalf of Concordia International Rx (UK) Limited, including its subsidiary Mercury Pharma Group Ltd. This request relates to Liothyronine Sodium 20mcg Tablets (“LT”). The marketing authorisation (“MA”) for LT is held by Mercury Pharma Group Ltd (under MA number PL 10972/0033). We refer to three occasions between November 2007 and June 2015 on which the Drug Tariff categorisation of LT was changed, and hereby make a FOIA request for the following information: 1.Details of the reasoning (and any related correspondence and/or other relevant documentation) in relation to the decision not to list LT in the Drug Tariff from December 2007 to November 2010. 2.Details of the reasoning (and any related correspondence and/or other relevant documentation) in relation to the decision to list LT in Category A of the Drug Tariff from November 2010 to May 2015. 3.Details of the reasoning (and any related correspondence and/or other relevant documentation) in relation to the decision to list LT in Category C of the Drug Tariff from May 2015 to the present day. Please note that, prior to being de-branded in October 2007, LT were sold under the brand name ‘Tertroxin’. To the extent that LT may have been listed in the Drug Tariff as Tertroxin after October 2007, we request the abovementioned information in respect of Tertroxin as well. Please provide the information and documents requested to: Humphrey Thomas Morgan, Lewis & Bockius UK LLP Condor House 5-10 St. Paul''s Churchyard London EC4M 8AL +442032015398 humphrey.thomas@morganlewis.com In accordance with Section 10(1) of the FOIA, we look forward to hearing from you promptly and in any event no later than twenty working days following your receipt of this request, i.e. by 31 January 2018. Yours faithfully Morgan, Lewis & Bockius UK LLP Acting on behalf of Concordia International Rx (UK) Limited, including its subsidiary Mercury Pharma Group Ltd. [On 31 January 2018 you clarified the following:]By “abovementioned information” it was meant: Details of the reasoning (and any related correspondence and/or other relevant documentation) in relation to: • the decision not to list Tertroxin in the Drug Tariff from December 2007 to November 2010; • the decision to list Tertroxin in Category A of the Drug Tariff from November 2010 to May 2015; and • the decision to list Tertroxin in Category C of the Drug Tariff from May 2015 to the present day. I should point out that our FOIA Request principally relates to Liothyronine Tablets. Tertroxin was the branded name of Liothyronine Tablets until September/October 2017 when the product was de-branded. The aspect of our FOIA Request relating to Tertroxin was made purely to account for instances in which Liothyronine Tablets may have been mistakenly referred to as Tertroxin (particularly in late 2007 shortly after the product was de-branded). I hope that is now clear.

Status: Complete
Response Date: 28 Mar 2018
Response: Please see attached response

References: